Skip to main content
. Author manuscript; available in PMC: 2023 Jan 26.
Published in final edited form as: Best Pract Res Clin Rheumatol. 2022 Jun 9;36(3):101754. doi: 10.1016/j.berh.2022.101754

Figure 4.

Figure 4

Outline of a recommended approach to sequential therapy: in a patient with severe osteoporosis at high imminent risk of fracture following fracture risk assessment, a bone forming agent for 1-2 years is recommended (duration according to prescribing guidelines). Following this, bone-forming therapy, a consolidation period of antiresorptive therapy (such as a bisphosphonate or denosumab) is recommended. Monitoring, including assessment of treatment adherence and reassessment of fracture risk, is required. Reproduced with permission from (73).